Can genetic-based advice help you lose weight? Findings from the Food4Me European randomized controlled trial
article
Celis-Morales, C.
Marsaux, C.F.M.
Livingstone, K.M.
Navas-Carretero, S.
San-Cristobal, R.
Fallaize, R.
Macready, A.L.
O'Donovan, C.
Woolhead, C.
Forster, H.
Kolossa, S.
Daniel, H.
Moschonis, G.
Mavrogianni, C.
Manios, Y.
Surwillo, A.
Traczyk, I.
Drevon, C.A.
Grimaldi, K.
Bouwman, J.
Gibney, M.J.
Walsh, M.C.
Gibney, E.R.
Brennan, L.
Lovegrove, J.A.
Martinez, J.A.
Saris, W.H.M.
Mathers, J.C.
Background: There has been limited evidence about whether genotype-tailored advice provides extra benefits in reducing obesityrelated traits compared with the benefits of conventional one-size-fitsall advice. Objective: We determined whether the disclosure of information on fat-mass and obesity-associated (FTO) genotype risk had a greater effect on a reduction of obesity-related traits in risk carriers than in nonrisk carriers across different levels of personalized nutrition. Design: A total of 683 participants (women: 51%; age range: 18'73 y) from the Food4Me randomized controlled trial were included in this analysis. Participants were randomly assigned to 4 intervention arms as follows: level 0, control group; level 1, dietary group; level 2, phenotype group; and level 3, genetic group. FTO (single nucleotide polymorphism rs9939609) was genotyped at baseline in all participants, but only subjects who were randomly assigned to level 3 were informed about their genotypes. Level 3 participants were stratified into risk carriers (AA/AT) and nonrisk carriers (TT) of the FTO gene for analyses. Height, weight, and waist circumference (WC) were self-measured and reported at baseline and months 3 and 6. Results: Changes in adiposity markers were greater in participants who were informed that they carried the FTO risk allele (level 3 AT/AA carriers) than in the nonpersonalized group (level 0) but not in the other personalized groups (level 1 and 2). Mean reductions in weight andWC at month 6 were greater for FTO risk carriers than for noncarriers in the level 3 group [-2.28 kg (95% CI: -3.06, -1.48 kg) compared with -1.99 kg (-2.19, -0.19 kg), respectively (P = 0.037); and -4.34 cm(-5.63, -3.08 cm) compared with -1.99 cm (-4.04, -0.05 cm), respectively, (P = 0.048)]. Conclusions: There are greater body weight and WC reductions in risk carriers than in nonrisk carriers of the FTO gene. This trial was registered at clinicaltrials.gov as NCT01530139. © 2017 American Society for Nutrition.
TNO Identifier
766491
ISSN
00029165
Source
American Journal of Clinical Nutrition, 105(5), pp. 1204-1213.
Pages
1204-1213
Files
To receive the publication files, please send an e-mail request to TNO Repository.